Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2

Morris E Feldman1, Beth Apsel, Aino Uotila

  • 1Howard Hughes Medical Institute and Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, USA.

Plos Biology
|February 13, 2009
PubMed

Insights

Novel mTOR inhibitors called TORKinibs target both mTORC1 and mTORC2 complexes, offering enhanced inhibition of cell growth and protein synthesis compared to rapamycin. These compounds reveal new rapamycin-resistant functions of mTORC1.

Area of Science:

  • Cellular Biology
  • Molecular Biology
  • Pharmacology

Background:

  • The mammalian target of rapamycin (mTOR) pathway is crucial for regulating cell growth, survival, and metabolism.
  • mTOR functions through two distinct complexes, mTORC1 and mTORC2, with differential sensitivity to inhibitors like rapamycin.
  • Current rapamycin-based therapies primarily target mTORC1, leaving mTORC2 effects less understood.

Purpose of the Study:

  • To investigate the effects of novel ATP-competitive mTOR kinase inhibitors (TORKinibs) on both mTORC1 and mTORC2.
  • To compare the efficacy of TORKinibs with rapamycin in inhibiting cell proliferation and key signaling pathways.
  • To elucidate new functional aspects of mTORC1 activity resistant to rapamycin.

Main Methods:

  • Utilized novel mTOR kinase domain inhibitors (TORKinibs PP242 and PP30) in cellular and animal models.
  • Assessed the phosphorylation status of Akt (a key downstream target) at specific sites (S473 and T308).
  • Measured protein synthesis rates, focusing on cap-dependent translation, and cell proliferation.

Main Results:

  • TORKinibs effectively inhibited both mTORC1 and mTORC2, leading to decreased Akt phosphorylation at S473 and reduced overall Akt activation.
  • TORKinibs demonstrated superior inhibition of primary cell proliferation compared to rapamycin.
  • PP242 showed enhanced mTORC1 inhibition and blocked cap-dependent translation more effectively than rapamycin.

Conclusions:

  • Novel TORKinibs provide potent inhibition of both mTORC1 and mTORC2, surpassing rapamycin's efficacy.
  • These inhibitors reveal previously uncharacterized rapamycin-resistant mTORC1 functions, particularly in regulating cap-dependent translation.
  • TORKinibs represent valuable pharmacological tools for studying mTOR signaling in physiology and disease, offering a complementary approach to rapamycin.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...